SPEED survey measures dry eye symptoms

Article

The Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire is a repeatable and valid method to measure dry eye symptoms, reveals a recent paper in the journal Cornea.

The Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire is a repeatable and valid method to measure dry eye symptoms, reveals a recent paper in the journal Cornea.

Dr William Ngo et al., Centre for Contact Lens Research, University of Waterloo, Waterloo, Ontario, Canada, conducted a study on 50 subjects, with 30 as identified as symptomatic and 20 asymptomatic. The SPEED questionnaire was used on all patients, as well as the McMonnies dry eye survey, the Ocular Surface Disease Index (OSDI), dry eye questionnaire and subjective evaluation of symptoms.

All questionnaires were completed in a random order two visits, with clinical measurements obtained on the first visit. Concordance correlation coefficient was used to determine repeatability, whereas Rasch analyses, principal component and factor was used to determine dimensionality. SPEED scores were compared with dry eye diagnosis based on OSDI to measure validity.

SPEED survey data was undimensional and repeatable, with the three principal symptoms of dry eye identified. This included dryness, burning and soreness/fatigue. The only clinical measures that strongly correlated with SPEED questionnaire scores were corneal staining, meibomian gland score and meibomian glands yielding liquid secretion score.

To read the abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.